Cargando…

Tracking 20 Years of Compound-to-Target Output from Literature and Patents

The statistics of drug development output and declining yield of approved medicines has been the subject of many recent reviews. However, assessing research productivity that feeds development is more difficult. Here we utilise an extensive database of structure-activity relationships extracted from...

Descripción completa

Detalles Bibliográficos
Autores principales: Southan, Christopher, Varkonyi, Peter, Boppana, Kiran, Jagarlapudi, Sarma A.R.P., Muresan, Sorel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812171/
https://www.ncbi.nlm.nih.gov/pubmed/24204758
http://dx.doi.org/10.1371/journal.pone.0077142
_version_ 1782288946127962112
author Southan, Christopher
Varkonyi, Peter
Boppana, Kiran
Jagarlapudi, Sarma A.R.P.
Muresan, Sorel
author_facet Southan, Christopher
Varkonyi, Peter
Boppana, Kiran
Jagarlapudi, Sarma A.R.P.
Muresan, Sorel
author_sort Southan, Christopher
collection PubMed
description The statistics of drug development output and declining yield of approved medicines has been the subject of many recent reviews. However, assessing research productivity that feeds development is more difficult. Here we utilise an extensive database of structure-activity relationships extracted from papers and patents. We have used this database to analyse published compounds cumulatively linked to nearly 4000 protein target identifiers from multiple species over the last 20 years. The compound output increases up to 2005 followed by a decline that parallels a fall in pharmaceutical patenting. Counts of protein targets have plateaued but not fallen. We extended these results by exploring compounds and targets for one large pharmaceutical company. In addition, we examined collective time course data for six individual protease targets, including average molecular weight of the compounds. We also tracked the PubMed profile of these targets to detect signals related to changes in compound output. Our results show that research compound output had decreased 35% by 2012. The major causative factor is likely to be a contraction in the global research base due to mergers and acquisitions across the pharmaceutical industry. However, this does not rule out an increasing stringency of compound quality filtration and/or patenting cost control. The number of proteins mapped to compounds on a yearly basis shows less decline, indicating the cumulative published target capacity of global research is being sustained in the region of 300 proteins for large companies. The tracking of six individual targets shows uniquely detailed patterns not discernible from cumulative snapshots. These are interpretable in terms of events related to validation and de-risking of targets that produce detectable follow-on surges in patenting. Further analysis of the type we present here can provide unique insights into the process of drug discovery based on the data it actually generates.
format Online
Article
Text
id pubmed-3812171
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38121712013-11-07 Tracking 20 Years of Compound-to-Target Output from Literature and Patents Southan, Christopher Varkonyi, Peter Boppana, Kiran Jagarlapudi, Sarma A.R.P. Muresan, Sorel PLoS One Research Article The statistics of drug development output and declining yield of approved medicines has been the subject of many recent reviews. However, assessing research productivity that feeds development is more difficult. Here we utilise an extensive database of structure-activity relationships extracted from papers and patents. We have used this database to analyse published compounds cumulatively linked to nearly 4000 protein target identifiers from multiple species over the last 20 years. The compound output increases up to 2005 followed by a decline that parallels a fall in pharmaceutical patenting. Counts of protein targets have plateaued but not fallen. We extended these results by exploring compounds and targets for one large pharmaceutical company. In addition, we examined collective time course data for six individual protease targets, including average molecular weight of the compounds. We also tracked the PubMed profile of these targets to detect signals related to changes in compound output. Our results show that research compound output had decreased 35% by 2012. The major causative factor is likely to be a contraction in the global research base due to mergers and acquisitions across the pharmaceutical industry. However, this does not rule out an increasing stringency of compound quality filtration and/or patenting cost control. The number of proteins mapped to compounds on a yearly basis shows less decline, indicating the cumulative published target capacity of global research is being sustained in the region of 300 proteins for large companies. The tracking of six individual targets shows uniquely detailed patterns not discernible from cumulative snapshots. These are interpretable in terms of events related to validation and de-risking of targets that produce detectable follow-on surges in patenting. Further analysis of the type we present here can provide unique insights into the process of drug discovery based on the data it actually generates. Public Library of Science 2013-10-29 /pmc/articles/PMC3812171/ /pubmed/24204758 http://dx.doi.org/10.1371/journal.pone.0077142 Text en © 2013 Southan et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Southan, Christopher
Varkonyi, Peter
Boppana, Kiran
Jagarlapudi, Sarma A.R.P.
Muresan, Sorel
Tracking 20 Years of Compound-to-Target Output from Literature and Patents
title Tracking 20 Years of Compound-to-Target Output from Literature and Patents
title_full Tracking 20 Years of Compound-to-Target Output from Literature and Patents
title_fullStr Tracking 20 Years of Compound-to-Target Output from Literature and Patents
title_full_unstemmed Tracking 20 Years of Compound-to-Target Output from Literature and Patents
title_short Tracking 20 Years of Compound-to-Target Output from Literature and Patents
title_sort tracking 20 years of compound-to-target output from literature and patents
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812171/
https://www.ncbi.nlm.nih.gov/pubmed/24204758
http://dx.doi.org/10.1371/journal.pone.0077142
work_keys_str_mv AT southanchristopher tracking20yearsofcompoundtotargetoutputfromliteratureandpatents
AT varkonyipeter tracking20yearsofcompoundtotargetoutputfromliteratureandpatents
AT boppanakiran tracking20yearsofcompoundtotargetoutputfromliteratureandpatents
AT jagarlapudisarmaarp tracking20yearsofcompoundtotargetoutputfromliteratureandpatents
AT muresansorel tracking20yearsofcompoundtotargetoutputfromliteratureandpatents